Iveta Palešová is a graduate of the University of Economics in Bratislava, Faculty of Business Management. Since 1995 she has been working in the pharmaceutical industry. She started her professional career at Janssen-Cilag, where she worked for several positions in finance, logistics and pricing in a regulated environment. Since 2008, she has been involved in drug pricing, market entry, pharmaco-economic budget and cost analyzes in various therapeutic areas, data processing on drug consumption development, complex medical costs, and treatment effects. She worked at Roche 2008-2014, Amgen 2014-2017, and Novaris from 2017 until now. She has recently been particularly involved in the advent of oncology drugs. She is an active member of the Association of Innovative Pharmaceutical Industries (AIFP), where she runs a group for Orphan Medicines and is a member of the  Association Board in Slovakia. AIFP presented at several expert events about the possibilities for regulation of drug consumption from the producer's perspective, the development of registered and paid medicines in Slovakia, the introduction and the terms of agreements about the therapeutic  risk between manufacturers and health insurance companies in Slovakia. In her free time she loves to read and travels with the family and friends.